How to Buy Kymera Therapeutics Stock
Kymera Therapeutics Inc
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics.
Kymera Therapeutics stock last closed at $113.51, down 0.6% from the previous day, and has increased 154.91% in one year. It has overperformed other stocks in the Biotechnology industry by 1.32 percentage points. Kymera Therapeutics stock is currently +209.71% from its 52-week low of $36.65, and -12.72% from its 52-week high of $130.05.
As of Jul 2, 2026, there are 82.26M shares of KYMR outstanding. The market value of KYMR is $9.34B. In the last 24 hours, 788,000 KYMR shares were traded.
How to Buy Kymera Therapeutics Stock
Wondering how to invest in Kymera Therapeutics stock? Here's how.
- Choose where to buy Kymera Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Kymera Therapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Select your payment method and add your details.
- Analyze Kymera Therapeutics stock: The Kymera Therapeutics ticker symbol is KYMR. Is Kymera Therapeutics stock a good investment? Should you buy shares of KYMR? How do KYMR's underlying business fundamentals look? Do top analysts think Kymera Therapeutics is a good buy? Why has KYMR's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if KYMR is a good stock to buy).
- Execute your KYMR purchase: Decide if you will purchase KYMR shares at the current market price or use a limit order to purchase KYMR shares at a given price.
- Monitor your investment in KYMR: Create a watchlist to keep track of your investment in Kymera Therapeutics stock.
Step 1: Choose where to buy Kymera Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy KYMR shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the right brokerage, it's time to fill out some personal details so you can invest in KYMR today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create your new brokerage account.
- Send your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on the best stock trading app, your next step is to transfer the money for your investment:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Analyze Kymera Therapeutics stock
Once you have selected the best place to buy Kymera Therapeutics stock, it's very important to research their stock prior to buying, so you truly understand the risk and opportunity.
Kymera Therapeutics Metrics
KYMR Fundamentals
WallStreetZen was designed to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on KYMR's stock page.
What is the fair value of KYMR stock?
You can use many financial metrics, analyses, models, and charts to gauge KYMR's intrinsic value.
Using relative valuations metrics:
- KYMR may be overvalued based on its P/B ratio of 6.06x, relative to Biotechnology industry P/B ratio of 5.6x
You can do more valuation research on KYMR's stock here.
KYMR Financial Summary
Positive Health Checks:
- KYMR has cash burn of 243997000. It has enough cash and short-term investments to cover this for at least one year.
- KYMR has $656.74M in cash and short term investments. This is enough to cover its annual cash burn of $244.00M.
- KYMR has a low debt to equity ratio of 0.08.
- There are more short-term assets than long-term liabilities on the KYMR balance sheet.
- There are more short-term assets than short-term liabilities on the KYMR balance sheet.
- Total KYMR debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
- KYMR profit margin has gone down from -409.1% to -612% in the past year.
Do analysts think it's a good time to buy Kymera Therapeutics stock
Out of 11 Equities analysts who give recommendations on KYMR, the consensus analyst rating on Kymera Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent KYMR Analyst Recommendations
Faisal Khurshid, a top 7% analyst from Jefferies assumes KYMR with a strong buy rating and lowers their KYMR price target from $122.00 to $110.00, on Mar 16, 2026.
David Dai, a top 24% analyst from UBS maintains KYMR with a strong buy rating and raises their KYMR price target from $90.00 to $128.00, on Mar 3, 2026.
Geoff Meacham, a top 7% analyst from Citigroup maintains KYMR with a strong buy rating and raises their KYMR price target from $110.00 to $120.00, on Mar 2, 2026.
Sudan Loganathan, a top 16% analyst from Stephens & Co. maintains KYMR with a strong buy rating and raises their KYMR price target from $95.00 to $100.00, on Mar 2, 2026.
Stephens & Co.'s Sudan Loganathan raised their price target on Kymera Therapeutics (NASDAQ: KYMR) by 5.3% from $95 to $100 on 2026/03/02. The analyst maintained their Strong Buy rating on the stock.
Kymera Therapeutics reported its Q4 and FY 2025 earnings.
Raising their price target, Loganathan said the results and management's guidance were aligned with prior guidance, keeping the 2026 investment narrative "largely unchanged."
Earnings Report
Kymera Therapeutics reported:
For Q4 2025:
- EPS of $(0.97), which missed the Zacks Consensus Estimate of $(0.77) and Q4 2024's $(0.88).
- Collaboration revenue of $2.9M, which missed the Zacks Consensus Estimate of $30M and Q4 2024's $7.39M.
For FY 2025:
- EPS of $(3.69), down from FY 2024's $(2.98).
- Collaboration revenue of $39.2M, down from FY 2024's $47.1M.
Management did not provide financial guidance in its press release.
President & CEO Nello Mainolfi, PhD, commented: “We set a high bar for what we wanted to achieve in 2025 and exceeded expectations.
"We enter this year with momentum and focus as we continue to advance an innovative and robust pipeline, anchored by our STAT6 program.
“Across many immuno-inflammatory diseases, patients face tradeoffs, often compromising on efficacy, safety, or convenience.
"We see an opportunity to change the status quo.
"With highly encouraging Phase 1b data in atopic dermatitis demonstrating consistent impact across every measure evaluated, and two parallel Phase 2b studies now underway in atopic dermatitis and asthma, KT-621 highlights the opportunity to meaningfully expand the reach to patients who need and deserve treatment, move therapy earlier in the disease journey, and ultimately improve outcomes for millions of patients.
“We also initiated dosing in the first-in-human Phase 1 healthy volunteer trial for KT-579, the first IRF5-directed mechanism to enter the clinic and a completely novel oral approach to addressing key drivers of multiple debilitating autoimmune conditions.
"Additionally, with our highly productive small molecule discovery engine, we’re poised to share at least one new high-value program later this year.
"All these exciting milestones underscore our momentum and commitment to transforming how common, lifelong immunological diseases are treated.”
Biren Amin, a bottom 6% analyst from Piper Sandler maintains KYMR with a strong buy rating and raises their KYMR price target from $125.00 to $140.00, on Feb 26, 2026.
You can dive deeper into what analysts are saying on the Kymera Therapeutics stock forecast page.
Metrics for Advanced KYMR Traders
How is KYMR performing as a company?
Last year, KYMR revenue was $51.48M. In the last five year, KYMR's revenue has grown by 0.86% per year. This was slower than the Biotechnology industry average of 30.69%.
Dive into KYMR's earnings and revenue performance here.
What are KYMR insiders up to?
Over the past 12 months, insiders at KYMR have sold more shares than they have bought.
Noah Goodman, Chief Business Officer of KYMR, was the latest KYMR insider to sell. They sold $387,328.81 worth of KYMR shares on Jul 1, 2026.
Get more info about who owns KYMR shares here.
Does KYMR stock generate passive income?
No, Kymera Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your KYMR purchase
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, place a limit order.
Click the Open Trade button and your broker will place your order.
If you want more info about investing in stocks on eToro, click the how to video below:
Step 6: Monitor your investment in KYMR
Now that you own some KYMR stock, you'll want to stay up-to-date on your new investment.
Start a watchlist to get alerted to the latest events about your KYMR stock.
KYMR Feed
How to Buy Stock in Kymera Therapeutics
To reiterate, here are the 6 steps to buy stock in Kymera Therapeutics:
- Choose where to buy Kymera Therapeutics stock
- Create a brokerage account
- Put funds into your brokerage account
- Analyze Kymera Therapeutics stock
- Execute your KYMR purchase
- Monitor your investment in KYMR
If you are looking for a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Kymera Therapeutics, create a watchlist today.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.